Al H Pintozzi Ii, ASST P.T. Preventive Medicine - Preventive Medicine/Occupational Environmental Medicine Medicare: Not Enrolled in Medicare Practice Location: 211 E Army Trail Rd, Bloomingdale, IL 60108 Phone: 615-778-4066 |
Dr. Robin J Robinson, M.D. Preventive Medicine - Occupational Medicine Medicare: Not Enrolled in Medicare Practice Location: 245 S Gary Ave, St. 200, Bloomingdale, IL 60108 Phone: 630-894-8404 Fax: 630-894-8026 |
News Archive
Galectin Therapeutics Inc. today announced it has closed its underwritten public offering of 1,333,361 units (including 173,916 units that were offered and sold by Galectin pursuant to the exercise in-full of the underwriter's over-allotment option) at a price to the public of $9.00 per unit, with each unit consisting of two common voting shares, par value $0.001 per share and one warrant to purchase one share of Common Stock.
Fighting clever parasites requires smart vaccines that can trigger critical immune responses. A University of Chicago-based research team has found a novel way to do that.
Think back to your last fight with someone you love. How did you feel afterwards? How did you behave? Conflict with a loved one often leaves a person feeling terrible and then behaving badly. So much so that these scenarios have become soap opera clich-s. After an argument, one partner may brood, slam the door, and then drive to a local bar to drown their sorrows in alcohol. These dramas rarely have happy endings. Given these stereotypes, how do people control their emotional reactions and prevent emotional storms and their attendant use of intoxicating substances?
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company's application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older.
› Verified 9 days ago